Investigative Ophthalmology & Visual Science Cover Image for Volume 61, Issue 7
June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Anterior to Back (A2B) Bleb-free Tube Shunt: Effectiveness in Pediatric Glaucomatous Eyes Refractory to Other Therapy
Author Affiliations & Notes
  • Mario Montelongo
    Opthalmology, WESMDPA Baptist Medical Center Glaucoma Service, San Antonio, Texas, United States
  • Lauren Chu
    Pepperdine University, Malibu, California, United States
  • Francesc March de Ribot
    Ophthalmology, Barcelona University Hospital, Barcelona, Catalonia, Spain
  • William Eric Sponsel
    Opthalmology, WESMDPA Baptist Medical Center Glaucoma Service, San Antonio, Texas, United States
    Vision Sciences, University of Incarnate Word, San Antonio, Texas, United States
  • Footnotes
    Commercial Relationships   Mario Montelongo, None; Lauren Chu, None; Francesc March de Ribot, None; William Sponsel, AJL (P)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 3143. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mario Montelongo, Lauren Chu, Francesc March de Ribot, William Eric Sponsel; Anterior to Back (A2B) Bleb-free Tube Shunt: Effectiveness in Pediatric Glaucomatous Eyes Refractory to Other Therapy. Invest. Ophthalmol. Vis. Sci. 2020;61(7):3143.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : We set out to assess the efficacy of a newly available commercial model of the anterior to back (A2B) shunt (AJL, Bilbao, SP) in lowering intraocular pressure (IOP) in pediatric patients.

Methods : IOP was measured using consistently using either icare TA01i rebound tonometer (icare, Oy, Finland) or Goldmann applanation tonometer (Haag-Streit USA, Mason, Ohio). All patients involved were afflicted by congenital glaucoma. Inclusion: all individuals under the age of 18 who had undergone A2B shunt placement that had previously failed other forms of glaucoma surgery. Change in IOP and number of medications used was assessed using paired t-test.

Results : 8 eyes of 8 patients were assessed (mean age 8 [range: 5mo-17yr]; 4M4F). A mean of 6.1 prior incisional glaucoma procedures had been performed at various centers on each eye without sustained success (3 anti-metabolite filtering procedures, 11 tube shunts, and 7 trans-cameral viscoelastic bleb-expansion tube shunt modifications [range 1-8 such modifications]). Subjects were being administered a mean of 2.7 IOP-lowering drops. At 1, 7, 30, 90, and 180 days after surgery, 85%, 80%, 85%, 66%, and 100% of patients maintained an IOP ≤ 21 mmHg, respectively. At these same time intervals IOP dropped from the baseline value of 36.9 ± 3.3 mmHg to 15.1 ± 3.8 (-21.7mmHg, -40%; p=0.01), 22.6 ± 9.3 (-14.2mmHg, -38%; p=0.38), 17.1 ± 1.2 (-19.7 mmHg, -46%; p=0.001), 19.5 ± 3.4 (-17.3mmHg, -52%; p=0.05), and 18.3 ± 1.3 (-18.54mmHg, 49%; p=0.01) respectively. Change in medication at 30, 90, and 180 days dropped from baseline of 2.75 to 0 at each interval (p<0.0001). (Fig. 1)

Conclusions : The A2B shunt is a silicone glaucoma device designed by Dr. William E Sponsel. It drains aqueous humor from the anterior chamber into the retrobulbar space by way of a poly-fenestrated large-bore tube. In this study we show the efficacy of this therapy in pediatric patients with congenital glaucoma. Glaucoma surgery in pediatric patients with congenital glaucoma is challenging and the retrobulbar shunt is an efficacious alternative. One of its primary advantages is that it makes use of a compartment with a more ideal healing profile. This study suggests that the use of this kind of shunt in children is as efficacious at lowering IOP after other forms of therapy have failed.

This is a 2020 ARVO Annual Meeting abstract.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×